Covid-19 roundup: An mR­NA play­er gets a boost out of the lat­est round of an­i­mal da­ta; Phase­Bio pulls the plug on treat­ment tri­al

The big tell for Cure­Vac $CVAC is com­ing up with a loom­ing ear­ly-stage read­out on their mR­NA Covid-19 vac­cine in the clin­ic. But for now they’ll make do with an up­beat as­sess­ment on the pre­clin­i­cal an­i­mal da­ta they used to get in­to the clin­ic.

Re­searchers for the Ger­man biotech say they got the high an­ti­body titers and T cell ac­ti­va­tion they were look­ing for, lin­ing up a ham­ster chal­lenge to demon­strate — in a sim­ple mod­el — that the vac­cine could pro­tect the fur­ry crea­tures. Like the oth­er mR­NA vac­cines, the drug sends in­struc­tions to spur cells to dec­o­rate them­selves with the dis­tinc­tive spike on the virus to elic­it an im­mune re­sponse.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.